Erasca, Inc. Total Liabilities
Erasca, Inc. (ERAS) had Total Liabilities of $73.19 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-11
- 2026-06-30: Liabilities $73.19M.
- 2026-03-31: Liabilities $67.71M.
- 2025-12-31: Liabilities $70.98M.
- 2025-09-30: Liabilities $72.52M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $73.19M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $67.71M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $70.98M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $72.52M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $73.13M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $71.74M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $79.03M 10-K · filed 2026-03-12 |
| 2024-09-30 | $78.85M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $74.66M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $81.61M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $78.61M 10-K · filed 2025-03-20 |
| 2023-09-30 | $80.43M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $77.96M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $81.09M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $103.06M 10-K · filed 2024-03-27 |
| 2022-09-30 | $81.11M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $49.76M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $50.81M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $44.89M 10-K · filed 2023-03-23 |
| 2021-09-30 | $38.96M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $19.58M 10-Q · filed 2021-08-26 |
| 2020-12-31 | $17.40M 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |